Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00132925 |
The purposes of this study are:
Condition | Intervention | Phase |
---|---|---|
Rhinitis, Allergic, Perennial |
Drug: Triamcinolone |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | An Efficacy and Safety Evaluation of Nasacort AQ 110 µg QD Children Ages 2-5 Years With Perennial Allergic Rhinitis |
Estimated Enrollment: | 460 |
Study Start Date: | November 2003 |
Estimated Study Completion Date: | February 2006 |
Ages Eligible for Study: | 2 Years to 5 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Subjects presenting with any of the following will not be included in the study:
Any waiver of these inclusion and exclusion criteria must be approved by the investigator and the sponsor on a case-by-case basis prior to enrolling the subject. This must be documented by both the sponsor and the investigator.
No subject will be allowed to enroll in this study more than once.
Study ID Numbers: | XRG5029C/3502 |
Study First Received: | August 18, 2005 |
Last Updated: | April 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00132925 |
Health Authority: | United States: Institutional Review Board |
allergic rhinitis |
Hypersensitivity Triamcinolone Acetonide Otorhinolaryngologic Diseases Respiratory Tract Infections Respiratory Tract Diseases Rhinitis, Allergic, Perennial |
Triamcinolone Hypersensitivity, Immediate Triamcinolone diacetate Rhinitis Triamcinolone hexacetonide Respiratory Hypersensitivity |
Anti-Inflammatory Agents Immune System Diseases Therapeutic Uses Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists |
Hormones Glucocorticoids Pharmacologic Actions Nose Diseases |